Tags

Type your tag names separated by a space and hit enter

Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities.
PLoS One. 2011; 6(8):e23085.Plos

Abstract

We estimated the effectiveness of four monovalent pandemic influenza A (H1N1) vaccines (three unadjuvanted inactivated, one live attenuated) available in the U.S. during the pandemic. Patients with acute respiratory illness presenting to inpatient and outpatient facilities affiliated with four collaborating institutions were prospectively recruited, consented, and tested for influenza. Analyses were restricted to October 2009 through April 2010, when pandemic vaccine was available. Patients testing positive for pandemic influenza by real-time RT-PCR were cases; those testing negative were controls. Vaccine effectiveness was estimated in logistic regression models adjusted for study community, patient age, timing of illness, insurance status, enrollment site, and presence of high-risk medical conditions. Pandemic virus was detected in 1,011 (15%) of 6,757 enrolled patients. Fifteen (1%) of 1,011 influenza positive cases and 1,042 (18%) of 5,746 test-negative controls had record-verified pandemic vaccination >14 days prior to illness onset. Adjusted effectiveness (95% confidence interval) for pandemic vaccines combined was 56% (23%, 75%). Adjusted effectiveness for inactivated vaccines alone (79% of total) was 62% (25%, 81%) overall and 32% (-92%, 76%), 89% (15%, 99%), and -6% (-231%, 66%) in those aged 0.5 to 9, 10 to 49, and 50+ years, respectively. Effectiveness for the live attenuated vaccine in those aged 2 to 49 years was only demonstrated if vaccination >7 rather than >14 days prior to illness onset was considered (61%∶ 12%, 82%). Inactivated non-adjuvanted pandemic vaccines offered significant protection against confirmed pandemic influenza-associated medical care visits in young adults.

Authors+Show Affiliations

Department of Preventive Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. marie.griffin@vanderbilt.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

21857999

Citation

Griffin, Marie R., et al. "Effectiveness of Non-adjuvanted Pandemic Influenza a Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities." PloS One, vol. 6, no. 8, 2011, pp. e23085.
Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One. 2011;6(8):e23085.
Griffin, M. R., Monto, A. S., Belongia, E. A., Treanor, J. J., Chen, Q., Chen, J., Talbot, H. K., Ohmit, S. E., Coleman, L. A., Lofthus, G., Petrie, J. G., Meece, J. K., Hall, C. B., Williams, J. V., Gargiullo, P., Berman, L., & Shay, D. K. (2011). Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PloS One, 6(8), e23085. https://doi.org/10.1371/journal.pone.0023085
Griffin MR, et al. Effectiveness of Non-adjuvanted Pandemic Influenza a Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities. PLoS One. 2011;6(8):e23085. PubMed PMID: 21857999.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. AU - Griffin,Marie R, AU - Monto,Arnold S, AU - Belongia,Edward A, AU - Treanor,John J, AU - Chen,Qingxia, AU - Chen,Jufu, AU - Talbot,H Keipp, AU - Ohmit,Suzanne E, AU - Coleman,Laura A, AU - Lofthus,Gerry, AU - Petrie,Joshua G, AU - Meece,Jennifer K, AU - Hall,Caroline Breese, AU - Williams,John V, AU - Gargiullo,Paul, AU - Berman,LaShondra, AU - Shay,David K, AU - ,, Y1 - 2011/08/12/ PY - 2011/05/26/received PY - 2011/07/05/accepted PY - 2011/8/23/entrez PY - 2011/8/23/pubmed PY - 2012/2/16/medline SP - e23085 EP - e23085 JF - PloS one JO - PLoS One VL - 6 IS - 8 N2 - We estimated the effectiveness of four monovalent pandemic influenza A (H1N1) vaccines (three unadjuvanted inactivated, one live attenuated) available in the U.S. during the pandemic. Patients with acute respiratory illness presenting to inpatient and outpatient facilities affiliated with four collaborating institutions were prospectively recruited, consented, and tested for influenza. Analyses were restricted to October 2009 through April 2010, when pandemic vaccine was available. Patients testing positive for pandemic influenza by real-time RT-PCR were cases; those testing negative were controls. Vaccine effectiveness was estimated in logistic regression models adjusted for study community, patient age, timing of illness, insurance status, enrollment site, and presence of high-risk medical conditions. Pandemic virus was detected in 1,011 (15%) of 6,757 enrolled patients. Fifteen (1%) of 1,011 influenza positive cases and 1,042 (18%) of 5,746 test-negative controls had record-verified pandemic vaccination >14 days prior to illness onset. Adjusted effectiveness (95% confidence interval) for pandemic vaccines combined was 56% (23%, 75%). Adjusted effectiveness for inactivated vaccines alone (79% of total) was 62% (25%, 81%) overall and 32% (-92%, 76%), 89% (15%, 99%), and -6% (-231%, 66%) in those aged 0.5 to 9, 10 to 49, and 50+ years, respectively. Effectiveness for the live attenuated vaccine in those aged 2 to 49 years was only demonstrated if vaccination >7 rather than >14 days prior to illness onset was considered (61%∶ 12%, 82%). Inactivated non-adjuvanted pandemic vaccines offered significant protection against confirmed pandemic influenza-associated medical care visits in young adults. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/21857999/Effectiveness_of_non_adjuvanted_pandemic_influenza_A_vaccines_for_preventing_pandemic_influenza_acute_respiratory_illness_visits_in_4_U_S__communities_ L2 - https://dx.plos.org/10.1371/journal.pone.0023085 DB - PRIME DP - Unbound Medicine ER -